ENXTPA:AMPLI

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Amplitude Surgical SA develops and markets products for orthopedic surgery.


Snowflake Analysis

Slightly overvalued with questionable track record.


Similar Companies

Share Price & News

How has Amplitude Surgical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AMPLI's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

36.1%

AMPLI

-11.5%

FR Medical Equipment

8.7%

FR Market


1 Year Return

-28.8%

AMPLI

42.8%

FR Medical Equipment

-2.4%

FR Market

Return vs Industry: AMPLI underperformed the French Medical Equipment industry which returned 47.4% over the past year.

Return vs Market: AMPLI underperformed the French Market which returned -3.8% over the past year.


Shareholder returns

AMPLIIndustryMarket
7 Day36.1%-11.5%8.7%
30 Day30.7%-1.9%15.9%
90 Day20.3%35.6%1.3%
1 Year-28.8%-28.8%42.8%42.8%-0.7%-2.4%
3 Year-61.8%-61.8%43.9%42.1%11.2%2.2%
5 Yearn/a144.9%139.2%31.1%14.3%

Price Volatility Vs. Market

How volatile is Amplitude Surgical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Amplitude Surgical undervalued compared to its fair value and its price relative to the market?

22.46x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AMPLI's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AMPLI's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AMPLI is good value based on its PE Ratio (22.5x) compared to the Medical Equipment industry average (47.3x).

PE vs Market: AMPLI is poor value based on its PE Ratio (22.5x) compared to the French market (15.1x).


Price to Earnings Growth Ratio

PEG Ratio: AMPLI's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: AMPLI is good value based on its PB Ratio (0.9x) compared to the FR Medical Equipment industry average (2.6x).


Next Steps

Future Growth

How is Amplitude Surgical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-158.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AMPLI's earnings are forecast to decline over the next 3 years (-158.3% per year).

Earnings vs Market: AMPLI's earnings are forecast to decline over the next 3 years (-158.3% per year).

High Growth Earnings: AMPLI's earnings are forecast to decline over the next 3 years.

Revenue vs Market: AMPLI's revenue (1.1% per year) is forecast to grow slower than the French market (3.9% per year).

High Growth Revenue: AMPLI's revenue (1.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AMPLI's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Amplitude Surgical performed over the past 5 years?

13.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AMPLI has a large one-off gain of €5.6M impacting its December 31 2019 financial results.

Growing Profit Margin: AMPLI became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: AMPLI has become profitable over the past 5 years, growing earnings by 13.5% per year.

Accelerating Growth: AMPLI has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: AMPLI has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-1.8%).


Return on Equity

High ROE: AMPLI's Return on Equity (3.4%) is considered low.


Next Steps

Financial Health

How is Amplitude Surgical's financial position?


Financial Position Analysis

Short Term Liabilities: AMPLI's short term assets (€82.3M) exceed its short term liabilities (€37.5M).

Long Term Liabilities: AMPLI's short term assets (€82.3M) do not cover its long term liabilities (€148.7M).


Debt to Equity History and Analysis

Debt Level: AMPLI's debt to equity ratio (118.6%) is considered high.

Reducing Debt: AMPLI's debt to equity ratio has reduced from 971.2% to 118.6% over the past 5 years.

Debt Coverage: AMPLI's debt is not well covered by operating cash flow (15.5%).

Interest Coverage: AMPLI's interest payments on its debt are not well covered by EBIT (0.7x coverage).


Balance Sheet


Next Steps

Dividend

What is Amplitude Surgical's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AMPLI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AMPLI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AMPLI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AMPLI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AMPLI's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.1yrs

Average management tenure


CEO

Olivier Jallabert (51yo)

5yrs

Tenure

€2,093,017

Compensation

Mr. Olivier Jallabert is the Founder of Amplitude Surgical SA and serves as its Chairman and has been its Chief Executive Officer since June 10, 2015. Mr. Jallabert is the Founder, Chief Executive Officer  ...


CEO Compensation Analysis

Compensation vs Market: Olivier's total compensation ($USD2.37M) is above average for companies of similar size in the French market ($USD326.62K).

Compensation vs Earnings: Olivier's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Olivier Jallabert
Founder5yrs€2.09m10.4% 8.2m
Philippe Garcia
CFO & Vice Chairman of Financeno datano datano data
Muriel Marmilloud
Chief Operating Officer1.67yrsno datano data
Thomas Serre
Technical Director2.08yrsno datano data
Bruno Jugnet
Vice President of Marketing & Sales1.42yrsno datano data
Sandrine Chenu
Human Resources Director2.08yrsno datano data

2.1yrs

Average Tenure

Experienced Management: AMPLI's management team is considered experienced (2.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Olivier Jallabert
Founder5yrs€2.09m10.4% 8.2m
Bertrand Pivin
Director5yrsno datano data
Daniel Caille
Independent Director5yrsno datano data
Annick Bitoun
Director5yrsno datano data

5.0yrs

Average Tenure

55yo

Average Age

Experienced Board: AMPLI's board of directors are considered experienced (5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Amplitude Surgical SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Amplitude Surgical SA
  • Ticker: AMPLI
  • Exchange: ENXTPA
  • Founded: 1997
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €79.231m
  • Shares outstanding: 47.73m
  • Website: https://www.amplitude-surgical.com

Number of Employees


Location

  • Amplitude Surgical SA
  • 11, Cours Jacques Offenbach
  • Valence
  • Rhône-Alpes
  • 26000
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AMPLIENXTPA (Euronext Paris)YesCommon StockFREURJun 2015
AMPLIpBATS-CHIXE (BATS 'Chi-X Europe')YesCommon StockGBEURJun 2015
0RAFLSE (London Stock Exchange)YesCommon StockGBEURJun 2015

Biography

Amplitude Surgical SA develops and markets products for orthopedic surgery. The company provides a range of orthopedic products for primary and revision surgery aimed at treating pathologies of the hip, knee, and lower extremities primarily for foot and ankle surgery. It offers knee and hip prostheses and implants for the foot and ankle. The company also provides AMPLIVISION, a computer-assisted surgical system; the i.M.A.G.E., a single-use made-to-measure instrument system; and the E.T.O.I.L.E, a technology platform for anterior approaches resulting in less-invasive surgery. In addition, its products include KNEEMAP systems for the measurement of knee kinematics; and instruments for fitting implants. The company sells its products through a network of distributors and agents in approximately 30 countries. It serves patients, surgeons, and healthcare facilities. Amplitude Surgical SA was founded in 1997 and is headquartered in Valence, France. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/06 00:07
End of Day Share Price2020/06/05 00:00
Earnings2019/12/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.